L
Lewis J. Rubin
Researcher at University of California, San Diego
Publications - 373
Citations - 60316
Lewis J. Rubin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Pulmonary hypertension & Bosentan. The author has an hindex of 101, co-authored 370 publications receiving 57044 citations. Previous affiliations of Lewis J. Rubin include University of Texas Health Science Center at San Antonio & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
Oral hydralazine therapy for primary pulmonary hypertension.
Lewis J. Rubin,Robert H. Peter +1 more
TL;DR: It is suggested that hydralazine can reduce pulmonary resistance in some patients with primary pulmonary hypertension and on repeat catheterizations three to six months later the hemodynamic effects persisted.
Journal ArticleDOI
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
TL;DR: Short-term bosentan treatment in a subgroup of patients with PAH secondary to CTD seems to have a favourable effect compared with placebo, and the long-term follow-up of these patients suggests that first-line bosENTan, with the subsequent addition of other PAH treatments if required, is safe for long- term treatment and may have a positive effect on outcome.
Journal ArticleDOI
Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension
Anastasia Anthi,Roberto F. Machado,Maria Jison,Angelo M. Taveira-DaSilva,Lewis J. Rubin,Lori A. Hunter,Christian J. Hunter,Wynona Coles,James S. Nichols,Nilo A. Avila,Vandana Sachdev,Clara C. Chen,Mark T. Gladwin +12 more
TL;DR: Patients with SCD-associated PH have both pulmonary arterial and venous PH associated with severe limitations in exercise capacity, likely compounded by interstitial lung fibrosis and severe anemia, and the use of the six-minute-walk distance as an index of PH and cardiopulmonary function is supported.
Journal ArticleDOI
Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Ronald J. Oudiz,Robert Schilz,Robyn J. Barst,Nazzareno Galiè,Stuart Rich,Lewis J. Rubin,Gérald Simonneau +6 more
TL;DR: Continuous subcutaneous infusion of treprostinil in patients with PAH associated with CTD improved exercise capacity, symptoms of PAH, and hemodynamics.
Journal ArticleDOI
Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
Ronald J. Oudiz,Nazzareno Galiè,Horst Olschewski,Fernando Torres,Adaani E. Frost,Hossein Ardeschir Ghofrani,David B. Badesch,Michael D. McGoon,Vallerie V. McLaughlin,Ellen B. Roecker,Brooke C. Harrison,Darrin Despain,Christopher Dufton,Lewis J. Rubin +13 more
TL;DR: Two years of ambrisentan treatment was associated with sustained improvements in exercise capacity and aLow risk of clinical worsening and death in patients with PAH and was generally well tolerated and had a low risk of aminotransferase abnormalities over the 2-year study period.